Eli Lilly and’s (LLY) “Overweight” Rating Reaffirmed at Piper Jaffray Companies

Eli Lilly and Company (NYSE:LLY)‘s stock had its “overweight” rating restated by equities research analysts at Piper Jaffray Companies in a research note issued on Friday, September 8th. They presently have a $105.00 price target on the stock, up from their previous price target of $103.00. Piper Jaffray Companies’ price target indicates a potential upside of 25.13% from the company’s current price.

Several other equities research analysts have also commented on LLY. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $92.00 price target on shares of Eli Lilly and in a research note on Tuesday, May 16th. Sanford C. Bernstein restated an “outperform” rating and issued a $88.00 price target on shares of Eli Lilly and in a research note on Sunday, May 21st. Jefferies Group LLC restated a “buy” rating on shares of Eli Lilly and in a research note on Tuesday, May 30th. TheStreet cut shares of Eli Lilly and from a “b+” rating to a “c” rating in a report on Wednesday, May 31st. Finally, BidaskClub upgraded shares of Eli Lilly and from a “sell” rating to a “hold” rating in a report on Wednesday, June 14th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $88.27.

Eli Lilly and (NYSE LLY) traded up 0.70% on Friday, hitting $83.91. The stock had a trading volume of 3,148,723 shares. The company has a market cap of $88.53 billion, a price-to-earnings ratio of 36.31 and a beta of 0.34. Eli Lilly and has a 52-week low of $64.18 and a 52-week high of $86.72. The company has a 50 day moving average price of $80.84 and a 200-day moving average price of $82.02.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. Eli Lilly and’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.86 earnings per share. On average, equities research analysts predict that Eli Lilly and will post $4.16 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Eli Lilly and’s (LLY) “Overweight” Rating Reaffirmed at Piper Jaffray Companies” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://ledgergazette.com/2017/09/23/eli-lilly-ands-lly-overweight-rating-reiterated-at-piper-jaffray-companies.html.

In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the firm’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00. Following the transaction, the insider now directly owns 124,049,283 shares in the company, valued at approximately $10,307,254,924.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 590,000 shares of company stock worth $48,551,300 over the last quarter. 0.20% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. MPS Loria Financial Planners LLC acquired a new stake in Eli Lilly and in the 2nd quarter worth $128,000. W. E. Donoghue & Co. LLC acquired a new stake in Eli Lilly and in the 2nd quarter worth $16,220,000. M Holdings Securities Inc. acquired a new stake in Eli Lilly and in the 2nd quarter worth $234,000. Achmea Investment Management B.V. grew its position in Eli Lilly and by 70.6% in the 2nd quarter. Achmea Investment Management B.V. now owns 54,884 shares of the company’s stock worth $4,515,000 after purchasing an additional 22,714 shares during the last quarter. Finally, Aldebaran Financial Inc. grew its position in Eli Lilly and by 16.7% in the 2

Several other equities research analysts have also commented on LLY. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $92.00 price target on shares of Eli Lilly and in a research note on Tuesday, May 16th. Sanford C. Bernstein restated an “outperform” rating and issued a $88.00 price target on shares of Eli Lilly and in a research note on Sunday, May 21st. Jefferies Group LLC restated a “buy” rating on shares of Eli Lilly and in a research note on Tuesday, May 30th. TheStreet cut shares of Eli Lilly and from a “b+” rating to a “c” rating in a report on Wednesday, May 31st. Finally, BidaskClub upgraded shares of Eli Lilly and from a “sell” rating to a “hold” rating in a report on Wednesday, June 14th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $88.27.

Eli Lilly and (NYSE LLY) traded up 0.70% on Friday, hitting $83.91. The stock had a trading volume of 3,148,723 shares. The company has a market cap of $88.53 billion, a price-to-earnings ratio of 36.31 and a beta of 0.34. Eli Lilly and has a 52-week low of $64.18 and a 52-week high of $86.72. The company has a 50 day moving average price of $80.84 and a 200-day moving average price of $82.02.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. Eli Lilly and’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.86 earnings per share. On average, equities research analysts predict that Eli Lilly and will post $4.16 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Eli Lilly and’s (LLY) “Overweight” Rating Reaffirmed at Piper Jaffray Companies” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://ledgergazette.com/2017/09/23/eli-lilly-ands-lly-overweight-rating-reiterated-at-piper-jaffray-companies.html.

In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the firm’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00. Following the transaction, the insider now directly owns 124,049,283 shares in the company, valued at approximately $10,307,254,924.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 590,000 shares of company stock worth $48,551,300 over the last quarter. 0.20% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. MPS Loria Financial Planners LLC acquired a new stake in Eli Lilly and in the 2nd quarter worth $128,000. W. E. Donoghue & Co. LLC acquired a new stake in Eli Lilly and in the 2nd quarter worth $16,220,000. M Holdings Securities Inc. acquired a new stake in Eli Lilly and in the 2nd quarter worth $234,000. Achmea Investment Management B.V. grew its position in Eli Lilly and by 70.6% in the 2nd quarter. Achmea Investment Management B.V. now owns 54,884 shares of the company’s stock worth $4,515,000 after purchasing an additional 22,714 shares during the last quarter. Finally, Aldebaran Financial Inc. grew its position in Eli Lilly and by 16.7% in the 2nd quarter. Aldebaran Financial Inc. now owns 5,950 shares of the company’s stock worth $490,000 after purchasing an additional 850 shares during the last quarter. Institutional investors own 75.72% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply